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THE ‘‘MARROW-MINER’’: EFFICACY OF A NOVEL, MINIMALLY INVASIVE
BONE MARROW HARVESTING DEVICE IN PRE-CLINICAL EVALUATION &
FIRST HUMAN EXPERIENCE
Kraft, D.L.1, Song, L.2, Crocker, M.4, Moseley, A.2, Long, M.2,
Vina, R.3, Ghazarossian, V.4 1Stanford University School of Medicine,
Stanford, CA; 2Stryker Orthopaedics; 3DRFV Foundation; 4StemCor
Systems.
Introduction: Bone marrow (BM) contains a rich supply of adult
stem and progenitor cells, and may have long-term advantages over
PBSC for many allo-transplants. Traditional percutaneous large
bore needle aspiration methods for harvesting marrow are crude, te-
dious and expensive and usually require general anesthesia. A novel
device, the MarrowMiner (MM) was developed for the minimally
invasive harvest of BM to enable the rapid, convenient, outpatient
harvest of large quantities of BM under local anesthesia for use in
BMT and an increasing array of regenerative therapies. The MM
has been tested extensively in human cadavers, in large animals, &
following recent FDA 510(k) approval, in initial human subjects.
Methods: In 5 juvenile pigs, standard 1 and 6-port needles were
used to aspirate marrow along the left iliac crest. On the right iliac,
the MM device was used to collect BM. Harvests were collected in:
small (5 ml), medium (6–20 ml), & large (.20 ml) volumes. BM vi-
ability, cell counts & CFU-F assays were performed. Initial human
subjects similarly had traditional needle harvests performed, fol-
lowed by MM harvest on their opposite hip.Results: In the porcine
study the MM was observed to be safe, with the catheter remaining
within the marrow cavity in up to 20 cm long passes..60 ml of mar-
row could be aspirated in a single pass. BM aspirated along the iliac
crest by the MM contained a significantly higher concentration of
nucleated cells and CFU/ml than by standard needles. As expected,
the CFU concentration decreased with increasing volume aspirated
by standard needles while no CFU dilution occurred with the MM.
The MM yielded significantly higher CFU/ml than the standard
needles with medium and large volume aspirates, where the MM
harvested 9 fold more CFU-F/ml than the 6-port needle (table).
In initial human subject experience, the MM was safe, effectively
collected BM, with no post-procedure pain or complications, and
higher CD341 counts compared to needle aspirates. Conclusions:
In a porcine model, the MM can successfully & safely harvest large
volumes of BM, with significantly higher stem cell content than tra-
ditional needle aspiration. The flexible shaft allowed for aspirating
BM of the highest cellularity along the iliac crest, a path unfeasible
for rigid needles. These results, as well as initial, ongoing clinical
studies suggest that this novel MM device may enable significantly
improved BM harvest in a more rapid, reproducible & less invasive
manner.
CFU/ml Content of Marrow from Traditional Harvest Aspirates and
from MarrowMiner
1 hole 6 hole MarrowMiner
Aspirate Size needle needle (MM)Small Volume 1111 ND ND
Medium Volume 516 1690 2623
Large Volume ND 226 2335
Along Ileac Crest NA NA 5313Mean CFU-F/ml (five, 65–75kg juvenile pigs).114
THE RATIO OF COLONY FORMING UNIT (CFU) TO TOTAL NUCLEATED
CELL (TNC) COUNT PREDICTS ENGRAFTMENT IN UMBILICAL CORD
BLOOD TRANSPLANT
Triplett, B.M., Regan, D.,Wofford, J., Schaeffler, J., Ferguson,W. Car-
dinal Glennon Children’s Medical Center, Saint Louis, MO.
Umbilical cord blood (UCB) is increasingly utilized as a graft
source for hematopoietic cell transplant; however, both graft failure
and delayed engraftment remain significant obstacles to successfulUCB transplantation. Graft characteristics correlated with im-
proved engraftment and survival include total nucleated cell dose
(TNC), degree of HLA match, CD341 cell dose, and colony-form-
ing unit assays (CFU). While TNC has been considered the most
consistent predictor of engraftment and survival, analysis of the rel-
ative contribution of these variables is complicated by the strong
correlation between TNC, CD341, and CFU doses. We hypothe-
size that the ratio of CFU to TNC is a cell dose-independent mea-
sure of graft hematopoietic potential that may be prognostically
useful in future graft selection algorithms.
The Saint Louis Cord Blood Bank has been performing CFU as-
says on all UCB units since 1996. Since 2002 the CFU/TNC ratio
has been utilized in our storage eligibility algorithm, with units hav-
ing\2 colonies/104 nucleated cells considered ineligible for bank-
ing. Engraftment data was analyzed for 237 acute leukemia patients
.10 kg who received a single UCB transplant after myeloablative
conditioning, and grouped into quartiles according to post-process-
ing CFU/TNC ratio. Patients without evidence of engraftment
were censored at day 60.
Median time to neutrophil engraftment (ANC . 500) became
shorter with each advancement in quartile (Table 1), and was 7
days faster in the highest CFU/TNC quartile compared to the low-
est (p 5 0.0007). A similar trend was seen in 66 patients with post-
thaw CFU data available. There was no difference in TNC dose,
degree of HLA match, or patient age amongst the four quartile
groups. CD341 cell dose was greater in the highest CFU/TNC
quartile compared to the lowest (P\ 0.05).
Several authors have shown a relationship between higher CFU
dose and faster engraftment. However, higher CFU dose is corre-
lated with higher TNC dose. This, in addition to inherent variabil-
ity in CFU testing, has led to the use of TNC dose but not CFU
dose for determining the best graft for use in UCB transplant.
We show that CFU/TNC ratio can be a powerful independent pre-
dictor of rapid engraftment. Further study will be required to deter-
mine if this parameter will allow identification of grafts with
relatively small cell doses that might still have the potential for suc-
cessful engraftment.
Table 1. Time to Neutrophil engraftment by CFU/TNC ratio
Post Processing Median Time to
Ratio Group n ANC . 500 (days)\6.0/104 57 26
6.0–7.7/104 58 24
7.7–9.3/104 62 21
.9.3/104 57 19115
COST EFFECTIVENESS OF COLLECTION STRATEGIES FOR CD341 PRO-
GENITOR CELL DETERMINATIONS IN AUTOLOGOUS HEMATOPOIETIC
PROGENITOR CELL TRANSPLANTATION
Griffin, D.L.1, Donnenberg, A.D.2, Smith, K.J.3 1University of Pitts-
burgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Cancer
Institute, Pittsburgh, PA; 3University of Pittsburgh School of Medicine,
Pittsburgh, PA.
Background: Peripheral CD34 counts can optimize timing for
collection of adult mobilized hematopoietic progenitor cell
(HPC) products for transplantation to treat hematological malig-
nancies. The ability to accurately predict a successful CD34 col-
lection can reduce the number of multiple low-CD341
collections, easing the burden of collection for the patient and
the collection and processing facilities. Our hypothesis is that in-
creasing the circulating CD341 threshold will result in a cost
savings over strategies of no threshold and the current threshold
of 4 CD341 cells/ml, while resulting in a greater proportion of
successful collections. Methods: A decision tree was programmed
in TreeAge Pro Suite 2006 v1.3 (TreeAge Software, Williams-
town, MA) and a cost analysis run comparing ‘‘no threshold’’ to
varying thresholds. Probabilities were determined from a dataset
